Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > sciatica treatment market
Get a free sample of Sciatica Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Sciatica Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The sciatica treatment industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy.
Some of the eminent market participants operating in the sciatica treatment industry include:
The nonsteroidal anti-inflammatory drugs (NSAIDs) segment was valued at USD 2 billion in 2023 and will continue to gain traction through 2032, as they are more cost-effective, and are known for their effectiveness in reducing pain and inflammation.
The global sciatica treatment industry was valued at around USD 4.8 billion in 2023 and is expected to reach around USD 10 billion by 2032, driven by the increasing prevalence of sciatica, coupled with growing awareness related to available treatments.
North America sciatica treatment market accounted for USD 2 billion in 2023, favored by healthcare education initiatives targeting both healthcare professionals and the public.
Abbott Laboratories, Amneal Pharmaceuticals LLC., Bayer AG, Bristol Myers Squibb, Eliem Therapeutics, Novartis AG, Pfizer Inc., Scilex Holding, Sinfonia Biotherapeutics, and Sorrento Therapeutics.